Dandelion Science — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Dandelion Science is an early-stage, private biotech pioneering a novel approach to treating brain disorders through its Generative Neuromodulation™ platform. The company leverages generative AI to design therapies that program neural network dynamics, seeking to move beyond the broad and often deleterious effects of conventional neurochemical treatments. Based in Zurich and Geneva with a corporate presence in Boston, Dandelion is building a strong research foundation through collaborations with prestigious institutions like the Wyss Center Geneva and EPFL. The company is currently in a pre-clinical, pre-revenue stage, focused on platform development and validating its core hypothesis that brain network dynamics can be precisely targeted and modulated.

Neurological DisordersPsychiatric DisordersSensory Restoration

Technology Platform

Generative Neuromodulation™ platform using AI to design non-invasive, personalized patterns of brain stimulation to program neural network dynamics and treat disorders.

Opportunities

The platform targets the massive and underserved market for neurological and psychiatric disorders, where current pharmacological treatments often have limited efficacy and significant side effects.

Success could enable a new class of precise, non-invasive, and personalized digital therapeutics, potentially disrupting both the CNS drug and medical device neuromodulation markets.

Risk Factors

The core scientific and technical risk is extremely high, as the concept of programming brain network dynamics with AI-designed stimulation is novel and unproven.

The company also faces significant regulatory uncertainty for a new therapeutic modality and intense competition from both large medtech firms and other neurotech startups.

Competitive Landscape

Dandelion operates in the competitive and fast-evolving neurotechnology space. It faces competition from established medical device companies (e.g., Medtronic, Abbott) with invasive neuromodulation devices, companies developing non-invasive neuromodulation (e.g., Magnus Medical, BrainsWay), and a growing number of AI-driven digital therapeutic and neurodiagnostic startups. Its differentiation hinges on the 'generative' AI aspect for therapy design.

More companies in AI / Machine Learning →More companies in Switzerland →